On August 31, 2023, representatives of JSC “National Holding QazBioPharm” held a meeting with representatives of Genertec Meheco in the People’s Republic of China. Sun Wenhui, General Director of the Overseas Pharmaceutical Department of China Meheco Corporation, presented an overview of the company’s activities. Following the discussion, both parties agreed to explore the possibility of localizing the production of pharmaceutical products from Genertec’s portfolio at Kazakhstani manufacturing facilities, as well as to consider several projects in the healthcare sector.

CHINA GENERAL TECHNOLOGY (GROUP) HOLDING, LTD (hereinafter referred to as GENERTEC) was founded in 1998 and is a key state-owned enterprise under the direct management of the central government. In December 2018, the Corporation was designated as a pilot enterprise for investment among all state-owned companies. By the end of 2022, the Corporation included 508 domestic and 77 foreign companies and organizations, 15 industrial subgroups and subordinate entities, and four publicly listed companies, namely SMTCL, CTTC, Genertec Universal Medical, and China Meheco Group. The total workforce of the Corporation is 80,000 employees.

In recent years, Genertec has focused on three main areas: advanced manufacturing and technological services, pharmaceuticals and healthcare, and trade and engineering services. The Corporation continues to improve its organizational structure and strengthen its innovation drive to promote high-quality development.

The system includes 343 medical institutions covering 26 provinces and cities, including 27 top-tier (Level III) hospitals and 69 secondary (Level II) hospitals.

There are more than 48,000 hospital beds available.

The network handles over 28 million outpatient and emergency visits annually, and approximately 1.2 million hospital discharges per year.